加载中
NASDAQHealthcareBiotechnology
最新数据
US$2.71
−US$0.28 · -9.36%
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
前收盘价
US$2.71
−US$0.28 · -9.36%
盘前
US$2.7854
+US$0.0754 · +2.78%
10月8日 8:05 ET
盘中时间采用ET。市场数据可能有所延迟。
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
日内区间
当前US$2.71
52周区间
当前US$2.71
盘中时间采用ET。市场数据可能有所延迟。
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
日内区间
当前US$2.71
52周区间
当前US$2.71
| 项目（USD） | 2025财年 |
|---|---|
| 营收 | 4万 USD |
| 毛利 | 4万 USD |
| 研究与开发 | 363.83万 USD |
| 销售、一般及管理费用 | 4285.44万 USD |
| 营业费用 | 5820.92万 USD |
| 利息收入 | 32.76万 USD |
| 利息支出 | 250.46万 USD |
| 折旧和摊销 | 3.65万 USD |
| 营业利润 | −5816.92万 USD |
| 净利润 | −6214.62万 USD |
公司数据更新于 2026年10月8日。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI153.44万0.00%2.3万亿 USD0.03%US$381.03-0.40%
Vanguard Extended Market ETFVXF92.96万0.00%954亿 USD0.05%US$233.49-1.56%
iShares Micro-Cap ETFIWC10.03万0.01%13.33亿 USD0.60%US$183.36-1.09%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM2万0.02%1.17亿 USD0.73%US$15.97-0.38%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
